跳至主要内容
临床试验/NCT03975257
NCT03975257已完成不适用

Application of Ectoin Lozenges (EHT02) in Patients With Oropharyngeal Allergic Symptoms

Bitop AG11 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2019年2月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bitop AG
入组人数
90
试验地点
11
主要终点
cumulative score of allergic symptoms of the lips evaluated by the patient

研究概览

简要总结

The goal of this multicentric, prospective, randomised, controlled study (§23b German Act on Medical Devices (MPG)) is to investigate the efficacy of Ectoin Lozenges (EHT02) in treatment and prevention of oropharyngeal allergic symptoms.

详细描述

The immune system of humans can show an overreaction to proteins from the environment (allergic reaction). Triggers of these allergic reactions may be e.g. pollen, dust mites, mold or animal hair. Common allergic symptoms include itchy, stuffy, runny nose, sneezing, itchy and watery eyes and respiratory complaints. Allergen-specific immunotherapy is the only treatment that eliminates the causes of allergic disease. An example of such immunotherapies is the sublingual immunotherapy (SLIT). During SLIT, side effects may occur such as local oropharyngeal reactions, e.g. manifesting as itching, swelling or irritation.

The current study aims to investigate the efficacy of Ectoin Lozenges (EHT02) in patients suffering from oropharyngeal allergic symptoms. The symptoms are induced by SLIT.

Patients are dedicated to one of three groups: a) preventive application of Ectoin Lozenges before SLIT-initiation, b) therapeutic application of Ectoin Lozenges after SLIT-initiation or c) control: SLIT-initiation without application of Ectoin Lozenges.

The symptoms itching, swelling and irritation of mouth, lips and throat will be documented by the patients once 30 minutes after SLIT-initiation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

cumulative score of allergic symptoms of the lips evaluated by the patient

时间窗: about 30 minutes after SLIT-initiation

about 30 minutes after SLIT-initiation patients will assess allergic symptoms of the lips (swelling, itching and irritation) on a 4 point scale (0=none to 3=severe)

cumulative score of allergic symptoms of the mouth evaluated by the patient

时间窗: about 30 minutes after SLIT-initiation

about 30 minutes after SLIT-initiation patients will assess allergic symptoms of the mouth (swelling, itching and irritation) on a 4 point scale (0=none to 3=severe)

cumulative score of allergic symptoms of the throat evaluated by the patient

时间窗: about 30 minutes after SLIT-initiation

about 30 minutes after SLIT-initiation patients will assess allergic symptoms of the throat (swelling, itching and irritation) on a 4 point scale (0=none to 3=severe)

次要结局

  • Incidence of adverse events/serious adverse events(through study visit (participation encompasses 1 visit of approx. 60 min duration))

研究者

发起方
Bitop AG
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验